Global Meningococcal Vaccines Market 2016-2020 with GSK, Pfizer & Sanofi Dominating - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Meningococcal Vaccines Market 2016-2020" report to their offering.

The global meningococcal vaccines market to grow at a CAGR of 13.07% during the period 2016-2020.

The report covers the present scenario and the growth prospects of the global meningococcal vaccines market for 2016-2020. To calculate the market size, the report considers the report considers the revenue generated from the sales of vaccines used to prevent meningococcal infections. The report also includes a discussion of the key vendors operating in this market.

Commenting on the report, an analyst from the research team said that the availability of combination vaccines is one of the key trends aiding to the growth of this market. Bacterial meningitis is caused by bacteria such as Haemophilus influenzae type B, meningococci, and pneumococci. Combination vaccines for meningitis target multiple causative agents, thereby preventing meningitis caused by these agents.

For instance, Menhibrix is approved to prevent invasive meningococcal disease caused by Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y. Thus, combination vaccines eliminate the need to administer individual vaccines. The lower the number of injections administered, the lower the frequency of injection site reactions, such as pain, increasing patient compliance. Increased compliance results in effective prevention of the disease. Combination vaccines also decrease the packaging and transportation expenditure associated with multiple individual vaccines. Collectively, these factors decrease the development and marketing costs of the vaccine and increase the market revenue by effective prevention of the disease.

Further, the report states that vaccine storage and handling issues is one of the major challenges, decreasing the sales of the vaccine in countries with poor affordability. Vaccines require cold conditions to stay efficacious and are likely to lose their potency if the temperature drops below 35.6 degrees Fahrenheit or goes above 46.4 degrees Fahrenheit. Inadequately stored vaccines lose their efficacy and can cause increased local reactions.

Key vendors

- GSK

- Pfizer

- Sanofi

Other prominent vendors

- Beijing Minhai Biotechnology

- Bio Med

- Hualan Biological Engineering

- Imunoloski Zavod

- JN International Medical

- Nuron Biotech

- Serum Institute of India

- Vacunas Finlay SA

- Merck

- GlycoVaxyn

- Baxter

For more information visit http://www.researchandmarkets.com/research/9b354l/global

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Vaccines

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Vaccines